Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Athersys to Host First Quarter 2013 Financial Results Call



Athersys to Host First Quarter 2013 Financial Results Call

CLEVELAND, April 18, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX)
today announced it will release its first quarter 2013 financial results at
approximately 4:00 PM (Eastern Time) on Tuesday, May 14, 2013, and host a
conference call shortly thereafter at 4:30 PM (Eastern Time) to review the
results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William
(B.J.) Lehmann, President and Chief Operating Officer, will host the call as
follows:

Date                              May 14, 2013
Time                              4:30 p.m. (Eastern Time)
Telephone access: U.S. and Canada 800-273-1254
Telephone access: International   973-638-3440
Access code                       43466670
Live webcast                      www.athersys.com, under the Investors
                                  section

A replay will be available for on-demand listening shortly after the
completion of the call until 11:59 PM (Eastern Time) on May 28, 2013, at the
aforementioned URL, or by dialing 800-585-8367 or 855-859-2056 in the U.S. and
Canada, from abroad, 404-537-3406, and entering access code 43466670.

About Athersys

Athersys is a clinical stage biotechnology company engaged in the discovery
and development of therapeutic product candidates designed to extend and
enhance the quality of human life. The Company is developing its MultiStem^®
cell therapy product, a patented, adult-derived "off-the-shelf" stem cell
product platform for disease indications in the cardiovascular, neurological,
inflammatory and immune disease areas. The Company currently has several
clinical stage programs involving MultiStem, including for treating
inflammatory bowel disease, ischemic stroke, damage caused by myocardial
infarction, and for the prevention of graft-versus-host disease. Athersys has
also developed a diverse portfolio that includes other technologies and
product development opportunities, and has forged strategic partnerships and
collaborations with leading pharmaceutical and biotechnology companies, as
well as world-renowned research institutions in the United States and Europe
to further develop its platform and products. More information is available at
www.athersys.com.

The Athersys, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4548.

CONTACT: William (B.J.) Lehmann, J.D.
         President and Chief Operating Officer
         Tel: (216) 431-9900
         bjlehmann@athersys.com
        
         Investor Relations:
         Lisa M. Wilson
         In-Site Communications
         Tel: (917) 543-9932
         lwilson@insitecony.com

company logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement